Hyperliquid Strategies Inc (PURR) Stock Price, Quote & News

Company Profile

Hyperliquid Strategies Inc., through its subsidiary, operates as a a biotechnology company that owns a platform for biologic medicines of single or bifunctional action. The company was incorporated in 2025 and is based in New York, New York.

Industry: Capital Markets

Sector: Financial Services

Address:

477 Madison Avenue, New York, United States

BillionerOfKing Feb. 20 at 10:13 PM

$PURR Current Stock Price: $4.29

0 · Reply

jazziii Feb. 19 at 3:18 PM

$PURR based on mnav vs peers this is buyable around 2

0 · Reply

jazziii Feb. 17 at 6:53 PM

$PURR would you pay 3x nav (of hype owned ) for this when other DATs even on profitable chains are a 1x nav or less? why

0 · Reply

ford11 Feb. 15 at 10:41 AM

$HYPE.X $HYPD $PURR

0 · Reply

Bangjobz Feb. 13 at 7:19 PM

$PURR let's go ya little bastard.

0 · Reply

Bazzzigar Feb. 12 at 5:52 PM

$PURR CIFR

1 · Reply

erevnon Feb. 12 at 3:57 PM

Cantor Fitzgerald maintains Hyperliquid Strategies $PURR at Overweight and raises the price target from $5 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

erevnon Feb. 12 at 1:21 PM

Chardan Capital maintains Hyperliquid Strategies $PURR at Buy and raises the price target from $8.15 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

ford11 Feb. 12 at 12:47 PM

$APLD $HYPD $PURR

0 · Reply

ford11 Feb. 12 at 12:20 PM

$HYPE.X $HYPD $PURR

0 · Reply

Hyperliquid Strategies Inc Reports Financial Results for the Quarter Ended December 31, 2025

Feb 5, 2026, 4:15 PM EST - 15 days ago

Hyperliquid Strategies Inc Announces Webcast to Discuss Results for the Quarter Ended December 31, 2025

Dec 8, 2025, 9:20 AM EST - 2 months ago

Hyperliquid Strategies Inc Announces $30 million Stock Repurchase Program

Dec 3, 2025, 5:45 PM EST - 2 months ago

Ex-Barclays CEO unpacks Hyperliquid: ‘The FUTURE of finance'

Dec 2, 2025, 4:30 PM EST - 2 months ago

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Nov 18, 2025, 9:00 AM EST - 3 months ago

Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting

Oct 15, 2025, 10:03 AM EDT - 4 months ago

Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma

Sep 19, 2025, 9:00 AM EDT - 5 months ago

Sonnet to Present at the MedInvest Biotech & Pharma Conference

Aug 11, 2025, 9:15 AM EDT - 6 months ago

Sonnet Releases Virtual Investor "What This Means" Segment

Aug 4, 2025, 8:40 AM EDT - 7 months ago

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Jul 14, 2025, 11:30 AM EDT - 7 months ago

Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?

Jul 14, 2025, 6:00 AM EDT - 7 months ago

Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

May 1, 2025, 9:00 AM EDT - 10 months ago

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

Apr 4, 2025, 9:00 AM EDT - 11 months ago

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Apr 1, 2025, 4:15 PM EDT - 11 months ago

Sonnet Announces Release of Corporate Update Video

Apr 1, 2025, 7:30 AM EDT - 11 months ago

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Mar 26, 2025, 9:05 AM EDT - 11 months ago

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Mar 19, 2025, 8:50 AM EDT - 1 year ago

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Mar 11, 2025, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 26, 2025, 9:00 AM EST - 1 year ago

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Feb 19, 2025, 8:35 AM EST - 1 year ago

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Feb 18, 2025, 9:15 AM EST - 1 year ago

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Feb 13, 2025, 8:30 AM EST - 1 year ago

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

Feb 13, 2025, 8:00 AM EST - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Jan 28, 2025, 9:05 AM EST - 1 year ago

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

Jan 22, 2025, 8:35 AM EST - 1 year ago

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 21, 2025, 9:05 AM EST - 1 year ago

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Dec 23, 2024, 9:20 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Dec 17, 2024, 8:50 AM EST - 1 year ago

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Dec 9, 2024, 3:42 PM EST - 1 year ago

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 9, 2024, 8:45 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

Dec 4, 2024, 9:20 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

Nov 12, 2024, 9:15 AM EST - 1 year ago

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

Nov 6, 2024, 1:20 PM EST - 1 year ago

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

Nov 6, 2024, 8:30 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Oct 17, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

Oct 9, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Oct 4, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

Sep 30, 2024, 9:00 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform

Sep 25, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

Sep 4, 2024, 9:15 AM EDT - 1 year ago

Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series

Aug 19, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer

Aug 14, 2024, 8:35 AM EDT - 1 year ago

Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Jul 24, 2024, 3:00 PM EDT - 1 year ago

Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

Jul 24, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study

May 28, 2024, 8:00 AM EDT - 1 year ago

Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting

May 20, 2024, 9:15 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

May 14, 2024, 4:15 PM EDT - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update

BillionerOfKing Feb. 20 at 10:13 PM

$PURR Current Stock Price: $4.29

0 · Reply

jazziii Feb. 19 at 3:18 PM

$PURR based on mnav vs peers this is buyable around 2

0 · Reply

jazziii Feb. 17 at 6:53 PM

$PURR would you pay 3x nav (of hype owned ) for this when other DATs even on profitable chains are a 1x nav or less? why

0 · Reply

ford11 Feb. 15 at 10:41 AM

$HYPE.X $HYPD $PURR

0 · Reply

Bangjobz Feb. 13 at 7:19 PM

$PURR let's go ya little bastard.

0 · Reply

Bazzzigar Feb. 12 at 5:52 PM

$PURR CIFR

1 · Reply

erevnon Feb. 12 at 3:57 PM

Cantor Fitzgerald maintains Hyperliquid Strategies $PURR at Overweight and raises the price target from $5 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

erevnon Feb. 12 at 1:21 PM

Chardan Capital maintains Hyperliquid Strategies $PURR at Buy and raises the price target from $8.15 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

ford11 Feb. 12 at 12:47 PM

$APLD $HYPD $PURR

0 · Reply

ford11 Feb. 12 at 12:20 PM

$HYPE.X $HYPD $PURR

0 · Reply

jazziii Feb. 11 at 4:45 PM

$PURR can anybody explain why this is good, why would you have faith, the mnav is also very high? "net loss of $317.9 million for the six months ended December 31, 2025, primarily attributable to $262.4 million in unrealized losses on HYPE tokens due to market volatility,"

1 · Reply

WallStreetLens Feb. 11 at 12:34 PM

$PURR Earnings Alert Hyperliquid Strategies just dropped earnings and made a big move in crypto: • Bought 5M $HYPE.X tokens at $25.9 each → $129.5M spent • Cash remaining: $125M Market reaction? Traders will be watching $HYPE.X price action closely — this is a major strategic allocation. Could signal confidence in the token while keeping plenty of dry powder.

0 · Reply

PolycarpFX Feb. 10 at 11:15 PM

$PURR

0 · Reply

PolycarpFX Feb. 9 at 10:55 PM

$HYPE.X $PURR

0 · Reply

jazziii Feb. 9 at 3:43 PM

$PURR ok grok told me. Not touching this, wait for 1.3x or lower. Dats have all cratered. "this time is different" believe if you want... "The current mNAV (market-to-Net Asset Value multiple) for PURR (Hyperliquid Strategies Inc., NASDAQ: PURR) is approximately 2.93x to 2.99x, based on the latest data from DefiLlama's Digital Asset Treasury tracker (as of February 9, 2026, around midday EST).Realized mNAV: ~2.93x–2.99x Realistic mNAV: ~2.93x–2.99x Max mNAV: ~3.18x–3.24x (depending on dilution/shares considered) This indicates PURR is trading at a strong premium to its underlying treasury value (primarily 12.57 million HYPE tokens valued at ~$410 million today, plus cash/reserves). "

0 · Reply

jazziii Feb. 9 at 3:41 PM

$PURR

0 · Reply

jazziii Feb. 9 at 3:35 PM

$PURR whats the mnav of purr

0 · Reply

StealthAssasin Feb. 9 at 8:07 AM

$PURR lacks material operating momentum, elevating risk.

0 · Reply

vmartin15 Feb. 6 at 8:42 PM

$PURR buy now, its still under radar, if btc gonna go up, this gonna be lifechanger

0 · Reply

Jstockdaddy Feb. 6 at 5:04 PM

$HYPD $HYPE.X $PURR looks like today’s the day

0 · Reply

saka11 Feb. 5 at 9:26 PM

$NIXX $PURR If this is true it means we will see $2 per share soon for NIXX so the note holders who are shorting can convert their notes to common shares. This is my interpretation of this.

2 · Reply

AllandaleCapital Feb. 5 at 8:24 PM

$NIXX 1993 Shukla Trust, Anada OM, New Horizon Ventures, Quartz Ventures and Rajiv Akhaury strike again, same thing happened at $PURR after they showed up in Aug 22. Buy notes and short company. live short interest 3.83%, watching for shameless pump off stockauthority call much higher

1 · Reply

Market Cap	498.35M
Revenue (ttm)	1.00M
Net Income (ttm)	-16.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,601.00%
Debt to Equity Ratio	0.00

Volume	2,660,700
Avg Vol	2,513,278
Day's Range	N/A - N/A
Shares Out	123.97M
Stochastic %K	31%
Beta	1.57
Analysts	Strong Sell
Price Target	$7.22